Amantadine Use for Tardive Dyskinesia in This Clinical Context
Amantadine can be cautiously used for tardive dyskinesia in this patient with schizophrenia on lurasidone, valproate, and trazodone, but requires careful monitoring for psychiatric deterioration and CNS side effects given the patient's underlying psychiatric disorder.
Evidence for Amantadine in Tardive Dyskinesia
The evidence supporting amantadine for TD is modest but consistent. A randomized, double-blind, placebo-controlled crossover study demonstrated that amantadine (100 mg) significantly reduced AIMS scores by 21.81% over 2 weeks, with improvements in facial/oral movements (5.5 to 4.2, p=0.002), extremity movements (4.18 to 2.8, p=0.000), and severity scores (2.04 to 1.54, p=0.002) 1. Critically, amantadine did not alter cognitive measures or worsen psychotic symptoms in this study 1.
Multiple systematic reviews support amantadine as having preliminary evidence for TD treatment 2, 3, 4. The 2017 expert review specifically notes that while significance requires further investigation, amantadine shows "possible improvements in TD" 3.
Critical Safety Concerns in Psychiatric Populations
The major caveat is that amantadine carries significant CNS risks in patients with psychiatric disorders. Multiple ACIP guidelines consistently warn that serious side effects (marked behavioral changes, delirium, hallucinations, agitation, seizures) have been observed most often in persons with "certain psychiatric disorders" 5, 6, 7, 5, 6, 7. These severe effects are associated with high plasma drug concentrations 6, 7.
Drug Interaction Considerations
Valproate (Depakote) in this regimen is actually favorable - it's listed as a mood stabilizer for agitation control and is generally better tolerated than other mood stabilizers 8. No significant pharmacokinetic interactions between amantadine and valproate are documented.
Trazodone is used for mood stabilization/agitation and has no documented problematic interactions with amantadine 8.
Lurasidone (Latuda) presents an interesting consideration. The FDA label explicitly warns about tardive dyskinesia risk with all antipsychotics and states "if signs and symptoms of tardive dyskinesia appear in a patient on LATUDA, drug discontinuation should be considered" 9. However, one case report suggests lurasidone may actually improve TD symptoms (AIMS score decreased from 20 to 8-9) when used as augmentation, possibly through 5-HT2A antagonism and preferential prefrontal cortex dopamine modulation 10.
Practical Implementation Algorithm
Step 1: Verify TD diagnosis
- Document baseline AIMS score
- Confirm movements are not acute EPS or withdrawal dyskinesia
- Rule out other movement disorders
Step 2: Consider first-line alternatives before amantadine
- The 2001 AACAP guideline recommends attempting to lower the antipsychotic dose or switch to an atypical antipsychotic as first-line management 11
- Since patient is already on lurasidone (an atypical), dose reduction should be considered first if clinically feasible
- The 2025 INTEGRATE guideline emphasizes early switching strategies for side effects 12
Step 3: If proceeding with amantadine
- Start at 100 mg daily (the dose used in the positive RCT) 1
- Monitor closely for psychiatric deterioration (weekly for first month)
- Assess AIMS score at baseline, 2 weeks, and monthly
- Watch for CNS side effects: nervousness, anxiety, insomnia, difficulty concentrating, hallucinations, agitation 6, 7
Step 4: Duration of trial
- The RCT showed benefit within 2 weeks 1
- If no improvement by 4 weeks, discontinue
- If effective, continue with ongoing monitoring
Common Pitfalls to Avoid
Do not use anticholinergics (benztropine, trihexyphenidyl) for TD - these are explicitly contraindicated and may worsen TD 8
Do not assume amantadine is benign - the psychiatric disorder itself is a risk factor for serious CNS adverse effects 6, 7
Do not ignore renal function - amantadine requires dose adjustment in renal insufficiency, with significantly prolonged half-life 5, 6
Do not use in untreated angle-closure glaucoma - amantadine has anticholinergic effects 6, 7
Alternative Considerations
If amantadine fails or is not tolerated, the evidence hierarchy suggests:
- VMAT2 inhibitors (valbenazine, deutetrabenazine) - now considered first-line for moderate-to-severe TD with Phase III trial evidence 3, 13, 14, 15
- Clozapine switch - has evidence for TD improvement and is recommended for treatment-resistant cases 2, 14, 15
- Benzodiazepines (clonazepam) - have preliminary evidence 2
The decision ultimately depends on TD severity, patient's psychiatric stability, and whether first-line strategies (dose reduction, switching) have been exhausted. Given the patient's complex psychiatric medication regimen, close collaboration between psychiatry and neurology is essential 15.